
Please try another search
Regeneron (REGN) closed at $449.53 in the latest trading session, marking a -1.34% move from the prior day. This move lagged the S&P 500's daily gain of 9.38%. At the same time, the Dow added 11.37%, and the tech-heavy Nasdaq gained 8.12%.
Coming into today, shares of the biopharmaceutical company had gained 7.11% in the past month. In that same time, the Medical sector lost 27.39%, while the S&P 500 lost 32.94%.
Investors will be hoping for strength from REGN as it approaches its next earnings release. In that report, analysts expect REGN to post earnings of $6.29 per share. This would mark year-over-year growth of 41.35%. Our most recent consensus estimate is calling for quarterly revenue of $2.13 billion, up 24.22% from the year-ago period.
REGN's full-year Zacks Consensus Estimates are calling for earnings of $29.21 per share and revenue of $8.90 billion. These results would represent year-over-year changes of +18.4% and +13.15%, respectively.
Investors might also notice recent changes to analyst estimates for REGN. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 6.09% higher within the past month. REGN is holding a Zacks Rank of #1 (Strong Buy) right now.
Investors should also note REGN's current valuation metrics, including its Forward P/E ratio of 15.6. This represents a discount compared to its industry's average Forward P/E of 25.06.
It is also worth noting that REGN currently has a PEG ratio of 0.89. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.41 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 63, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow REGN in the coming trading sessions, be sure to utilize Zacks.com.
Shares of Caesars Entertainment (NASDAQ:CZR), a leading gambling stock, traded around 3% higher on Wednesday morning, though the stock was trading around 1.5% lower shortly before...
Amazon (NASDAQ:AMZN) is making a significant push into the future with a robust investment in robotics and artificial intelligence. The company has earmarked $35 billion for...
Home Depot’s (NYSE:HD) Q4 2024 report and guidance for 2025 have plenty to be unhappy about, but the simple truth is that this company turned a corner in 2024. It is on track for...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.